HUE032398T2 - Gyulladásos állapotok kezelésére alkalmas dimetil-benzoesav vegyületek - Google Patents
Gyulladásos állapotok kezelésére alkalmas dimetil-benzoesav vegyületek Download PDFInfo
- Publication number
- HUE032398T2 HUE032398T2 HUE13734249A HUE13734249A HUE032398T2 HU E032398 T2 HUE032398 T2 HU E032398T2 HU E13734249 A HUE13734249 A HU E13734249A HU E13734249 A HUE13734249 A HU E13734249A HU E032398 T2 HUE032398 T2 HU E032398T2
- Authority
- HU
- Hungary
- Prior art keywords
- methyl
- dimethyl
- amino
- mmol
- reduced pressure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Claims (5)
- Gyulladásos illegetak kezelésére ääism «.linieltl-beMoem1 vegyüieMk SzsfeOiimi !gOyp«ak;kégteil végyûJei tkol A jeOitese: ' vagykepfeti ezöpüft; R! jöeaöxe OX. OA, zsgy F; R'Fjelerîléee i:i ÇBj, Ogy F ; i.;i jelealéee CHsv OC-I A, Öli F ; R4 jáfeMéee ()H v&gy CMjOli le X jôeekHe CH ¥^gy H; vagy agy gyógy âmiEIgg ellggalhaiá sója. Egy L igenyponi ssennü vegyük!, silói Ás képkui csoport5. A/. I. v;.igy 2. igénypont amist vegyük! vagy sága, ahol ló jelcnkre C/iR 4, ás X-3> ig$it$$0fú®k
- 3, Λ a 1 "k igmyposlók bfesvlyifeesmink vvgyükt. vagy sója;, alió! B3 kkpiése H es 1E jeksuvsv HR
- 6. As 1. igéóypcmi ssersui vegyük;, ;no:ly:képkük vagy sPfs, X As L igénypont sgermM vegyüld, ínak: képiéin.8- A 7, igénypont szerinti hidratált vegyüJat. A Λ 8. igénypont »mim« hiduuH \s.gvúkL moU Τ'αKa ívnasvd ιλ EMíkm Λ - rm is. bozo pOÉsl^ntgenditTraktÂitei^l.^feêi rÂ|ÂdîÉ>àkmdî> spdtfnimánan 9M- zAata űlltrakéiös saip^él;miAallényege®iBaKÍ^APk Agy 74gÿ több, S.8A > t s J > ! EV, |/J% gs 24 ? kívül vïktvMî? ?-teta doYrakuOs tőgyei kombméE5 10* Igf Ikic IfÄyplÄ SMáMi *&g3HS$&f$£y gy^gyasz&ulag ellogadnmu $óia terápiában történő alkalmazásra.
- 11. Egy 1 -9. tgénypcmíök bármelyike érinti vegy&iet vagy gyógyasxauiag eltagadható soja kezelésében történő aikaiomzásrm tik F.gy 1'9. Ígéri)pontok KimV} Ac vcnnn \*g>ú!et vagy k vegyészünkig eltagadható sója rheumatoid arthritis kezelésében történő alkalmazásra; II. Egy í"#. Igénypontok bármelyHm vrerimi vegyidet vagy gyögyá^/atíiag eltagadható sósa oé®arllmdsS“Mei vagy rheumatoid arthstas-vd ösvetüggö dudálom kezelésében történő afkétmâzàsm.
- 14. Egy k9> igénypontok bármelyike szerinti χ együiet s agy yyogydszalilag elfogadható sója cos '-a ex több ex* oxav.m: n etav seb sv h* <v\ve - cl hgu w zeneixag> -oyi damaged ksmbénáciobim.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665956P | 2012-06-29 | 2012-06-29 | |
| US201361778969P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE032398T2 true HUE032398T2 (hu) | 2017-09-28 |
Family
ID=48746667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13734249A HUE032398T2 (hu) | 2012-06-29 | 2013-06-20 | Gyulladásos állapotok kezelésére alkalmas dimetil-benzoesav vegyületek |
Country Status (41)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110015221A1 (en) * | 2003-12-23 | 2011-01-20 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| PL3083554T3 (pl) | 2013-12-17 | 2019-08-30 | Eli Lilly & Company | Związki kwasu dimetylobenzoesowego |
| WO2016037954A1 (de) * | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| TWI770157B (zh) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| CA3059273A1 (en) * | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
| CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| HUE056382T2 (hu) | 2017-05-18 | 2022-02-28 | Idorsia Pharmaceuticals Ltd | Pirimidin-származékok mint PGE2 receptor modulátorok |
| MX2019013639A (es) | 2017-05-18 | 2020-01-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos. |
| TW201900179A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 |
| DK3625222T3 (da) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | Phenylderivater som pge2-receptormodulatorer |
| TW202228674A (zh) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270615B (it) | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
| JP2000355551A (ja) * | 1999-06-15 | 2000-12-26 | Nikken Chem Co Ltd | 医薬組成物 |
| PT1664016E (pt) | 2003-09-22 | 2008-12-29 | Euro Celtique Sa | Agentes terapêuticos úteis para tratamento da dor |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| WO2007143825A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| US8030489B2 (en) * | 2007-03-26 | 2011-10-04 | Astellas Pharma Inc. | Ornithine derivative |
| WO2012004293A2 (de) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insektizide und fungizide wirkstoffkombinationen |
| EP2681205B1 (en) | 2011-03-03 | 2016-11-16 | Universität des Saarlandes | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
-
2013
- 2013-06-11 TW TW102120796A patent/TWI572597B/zh not_active IP Right Cessation
- 2013-06-13 AR ARP130102078 patent/AR091431A1/es unknown
- 2013-06-13 JO JOP/2013/0178A patent/JO3221B1/ar active
- 2013-06-20 PT PT137342499T patent/PT2867218T/pt unknown
- 2013-06-20 KR KR1020147036136A patent/KR101634032B1/ko active IP Right Grant
- 2013-06-20 US US13/922,277 patent/US8642768B2/en not_active Expired - Fee Related
- 2013-06-20 ME MEP-2017-83A patent/ME02655B/me unknown
- 2013-06-20 LT LTEP13734249.9T patent/LT2867218T/lt unknown
- 2013-06-20 DK DK13734249.9T patent/DK2867218T3/en active
- 2013-06-20 EA EA201492140A patent/EA025531B1/ru not_active IP Right Cessation
- 2013-06-20 ES ES13734249.9T patent/ES2623099T3/es active Active
- 2013-06-20 MX MX2014015952A patent/MX347476B/es active IP Right Grant
- 2013-06-20 RS RS20170231A patent/RS55756B1/sr unknown
- 2013-06-20 SG SG11201408629QA patent/SG11201408629QA/en unknown
- 2013-06-20 CA CA2875572A patent/CA2875572C/en not_active Expired - Fee Related
- 2013-06-20 NZ NZ701894A patent/NZ701894A/en not_active IP Right Cessation
- 2013-06-20 PE PE2014002531A patent/PE20150185A1/es active IP Right Grant
- 2013-06-20 WO PCT/US2013/046685 patent/WO2014004230A1/en active Application Filing
- 2013-06-20 EP EP13734249.9A patent/EP2867218B1/en active Active
- 2013-06-20 JP JP2015520305A patent/JP6114824B2/ja active Active
- 2013-06-20 MY MYPI2014703973A patent/MY172860A/en unknown
- 2013-06-20 PL PL13734249T patent/PL2867218T3/pl unknown
- 2013-06-20 BR BR112014029551A patent/BR112014029551A2/pt not_active IP Right Cessation
- 2013-06-20 HU HUE13734249A patent/HUE032398T2/hu unknown
- 2013-06-20 IN IN2356MUN2014 patent/IN2014MN02356A/en unknown
- 2013-06-20 AP AP2014008165A patent/AP4063A/en active
- 2013-06-20 SI SI201330576A patent/SI2867218T1/sl unknown
- 2013-06-20 AU AU2013280779A patent/AU2013280779B2/en not_active Ceased
- 2013-06-20 CN CN201380030138.XA patent/CN104334540B/zh not_active Expired - Fee Related
- 2013-12-04 US US14/096,469 patent/US8933098B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 ZA ZA2014/08631A patent/ZA201408631B/en unknown
- 2014-11-28 TN TN2014000500A patent/TN2014000500A1/fr unknown
- 2014-12-03 CR CR20140554A patent/CR20140554A/es unknown
- 2014-12-11 IL IL236218A patent/IL236218A/en active IP Right Grant
- 2014-12-17 DO DO2014000286A patent/DOP2014000286A/es unknown
- 2014-12-17 GT GT201400289A patent/GT201400289A/es unknown
- 2014-12-18 CO CO14278424A patent/CO7160064A2/es unknown
- 2014-12-26 CL CL2014003537A patent/CL2014003537A1/es unknown
-
2015
- 2015-01-05 PH PH12015500008A patent/PH12015500008A1/en unknown
- 2015-05-07 HK HK15104360.7A patent/HK1203936A1/xx not_active IP Right Cessation
-
2017
- 2017-04-03 HR HRP20170540TT patent/HRP20170540T1/hr unknown
- 2017-04-12 CY CY20171100435T patent/CY1118830T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2867218T3 (en) | Dimethyl benzoic acid compounds useful for treating inflammatory conditions | |
| EP3083554B1 (en) | Dimethylbenzoic acid compounds | |
| TWI599561B (zh) | 苯氧基乙基哌啶化合物 | |
| RU2479576C9 (ru) | Амидное соединение | |
| US9000043B2 (en) | Phenoxyethoxy compounds | |
| JP6212644B2 (ja) | フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性 | |
| BRPI0712332A2 (pt) | composto e derivados farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto | |
| HUE033574T2 (hu) | Fenoxietil-dihidro-1H-izokinolin-vegyületek | |
| WO2005073183A1 (ja) | アリールスルフィド誘導体 | |
| AU2014265762B2 (en) | Phenoxyethyl dihydro-1H-isoquinoline compounds |